<DOC>
	<DOCNO>NCT01317433</DOCNO>
	<brief_summary>The aim study test role cycline prevention acne-like skin rash metastatic colorectal patient treat Cetuximab intensify FOLFIRI .</brief_summary>
	<brief_title>Pre-emptive Cycline Treatment Cetuximab Induced Skin Toxicity Colorectal Cancer</brief_title>
	<detailed_description>Cetuximab , Epidermal Growth Factor Receptor ( EGFR ) inhibitor , show improve FOLFIRI efficacy 59.3 % OR , wild KRAS patient advance colorectal cancer . Skin toxicity occur 81.6 % patient acne-like skin rash develop face trunk induce pain , decrease quality life drug compliance . Over 104 patient enrol phase II clinical trial sponsor Center Paul Papin ( NCT 00 559741 ) , grade &gt; = 2 cetuximab-acneiform rash occur 51 patient ( 49 % ) . In trial Cetuximab combine FOLFIRI intensify ( 5-FU intensification base pharmacokinetics pharmacogenetic study UGT1A1 status DPD ) . Until , pre-emptive skin toxicity treatment cycline demonstrate . Because cycline 's anti inflammatory property use inflammatory acne , cycline could prevent cetuximab-induced skin rash . In randomized double-blind placebo-controlled phase III trial , Jatoi et al. , fail highlight cycline effect 61 patient . On hand , STEPP study ( 95 pt ) show impact cycline prevent panitumumab relate skin toxicity . Our primary objective reduce incidence grade &gt; = 2 acne-like skin rash 30 % 6 week pre-emptive cycline treatment patient metastatic colorectal cancer undergo cetuximab therapy .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Doxycycline</mesh_term>
	<criteria>Advanced metastatic colorectal cancer , histologically confirm , first second metastatic line KRAS wildtype Adjuvant prior chemotherapy allow provided toxicity grade &lt; = 1 ( except alopecia neuropathy ) Age 18 80 year WHO Performance Status &lt; = 2 Complete initial assessment first treatment administration image pharmacogenetic , within 15 day biology , within 7 day clinical examination . Haematologic hepatic parameter : neutrophil &gt; = 1500 /mm3 , platelet &gt; = 100000/mm3 , Total bilirubin &lt; 2 x ULN , AST ALT &lt; = 3 x ULN , APL &lt; = 5 x ULN Absence total dihydropyrimidine dehydrogenase deficiency Patient able comply study requirement Signed write informed consent History presence cancer , except cutaneous cancer ( basocellular carcinoma ) , situ cancer cervix breast cancer curatively treat Any concomitant anticancer therapy Prior anti EGFR therapy , anti angiogenic therapy allow Prior cyclines hypersensitivity Treatment cyclines within 7 day randomization Presence rash randomization time Symptomatic uncontrolled ventral nervous system metastases Total dihydropyrimidine dehydrogenase deficiency No recovery toxicity Grade &lt; = 1 related past anticancerous treatment except alopecia neuropathy Active inflammatory bowel disease bowel Significant serious pathology unstable medical condition ( cardiac pathology uncontrolled , myocardial infarction within 6 month enrollment , systemic active uncontrolled infection ) atropine contraindication investigational agent without market authorization within 4 week enrollment Patient pregnant breast feed Woman man childbearing potential consenting use adequate contraceptive precaution study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>Metastatic Colorectal Cancer</keyword>
	<keyword>K-RAS wild-type</keyword>
	<keyword>FOLFIRI</keyword>
	<keyword>Cetuximab</keyword>
</DOC>